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Primary central nervous system (CNS) melanoma is a rare condition that accounts for only 1% of all melanomas. A 34-year-old Korean female
presented with a two-month history of progressive weakness in both legs. Spinal magnetic resonance image (MRI) revealed a spinal cord tumor
at the level of T4, which was hyperintense on T1-weighted imaging and hypointense on T2-weighted imaging. The intradural and extramedullary
tumor was completely resected and diagnosed as melanoma. There were no metastatic lesions. At three years after surgery, the patient is still
alive, with no evidence of tumor recurrence. We present the details of this case along with a comprehensive review of spinal cord melanoma.
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INTRODUCTION
Although metastatic melanoma is the third most common
cause of central nervous system (CNS) metastases, primary
CNS melanoma is rare and accounts for only 1% of all mela-
nomas4,10). Primary spinal cord melanoma is even rarer, but
has been reported previously4,10). We found 38 relevant articles
on primary spinal cord melanoma using Medline search and
found 3 Korean articles reported domestically. However,
none of these reports studied a large number of patients. The
largest series addressed only 5 cases11). Therefore, the precise
incidence, treatment, and prognosis are still unclear. The pur-
pose of this study was to present a comprehensive review of
all relevant articles along with our case.
CASE REPORT
A 34-year-old Korean woman was admitted for truncal
numbness and progressive weakness in both legs. She had
suffered from numbness in her right leg in the past and had
been medicated for twelve months prior to admission. Her
past medical history was unremarkable. She underwent a
lumbar magnetic resonance image (MRI) scan at another
hospital six months after symptoms began. The MRI scan
revealed no abnormality, but her symptoms became progres-
sively worse. She developed weakness in both legs and trun-
cal numbness below the T4 level two months before admis-
sion. Thoracic MRI scan revealed a solid intramedullary
lesion at the T4 level (Fig. 1), which showed slightly increas-
ed signal intensity on T1-weighted imaging, hypointense on
T2-weighted imaging, and homogenously enhancing follow-
ing gadolinium injection. Neurological examination revealed
grade 3/5 strength in the right leg and grade 4/5 strength in
the left leg associated with hypesthesia below the T4 level.
Deep tendon reflexes were normal and sphincter function
was intact. Absence of a primary origin outside the spinal cord
was confirmed after dermatological, ophthalmological, and
gastrointestinal examinations and positron emission tomog-
raphy scanning. The patient underwent T4 laminectomy.
After dural incision, a dark-pigmented mass was noted on
the surface of the spinal cord. The mass was dissected along a
cleavage plane and was completely resected. The mass was
black-colored, well-demarcated, and soft. Pathological exami-
nation revealed epitheloid tumor cell proliferation with dense
deposition of melanin granules (Fig. 2). Nuclear pleomor-
phism and mitoses were also noted. The patient’s postoperative
course was uneventful, and no adjuvant therapy was perform-
ed. She was followed in our outpatient clinic on a frequent
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basis, and she improved to walking status without assistance.
At three years after surgery, the patient was free of clinical
signs of metastasis, and postoperative MRI showed no
recurrence (Fig. 3).
DISCUSSION
Incidence
Primary melanoma of the CNS is rare, accounting for only
1% of all melanoma cases4,10). The incidence of primary spinal
cord melanoma cannot be found in the literature, but it would
be extremely rare. All published surgi-
cal cases are summarized in Table 1.
The characteristics of cases described in
unavailable articles are described thro-
ugh reference to other articles that rev-
iewed the relevant cases. Sex ratio was
1 : 1 (male : female). The mean age was
54 years and ranged from 20 to 80
years. Thoracic cases were most com-
mon (42.3%) followed by cervical
cases (34.6%), thoracolumbar cases
(11.5%), cervicothoracic cases (7.7%),
and lumbar cases (3.8%). Exophytosis
was present in 50% of reviewed cases.
It appears that primary spinal cord mel-
anoma usually arises from the leptome-
ninges, regardless of its precise cellular
origin. It is believed that primary mela-
noma of the spinal cord arises either
from leptomeningeal melanoblasts or
from neuroectodermal congenital
rests15,22). Leptomeningeal melanoblasts
penetrate the spinal cord with the vas-
cular bundles5). Epidermal melano-
blasts reach the leptomeninges when
the neural crest is formed.
Diagnosis
The clinical symptoms are non-specific10). Progressive
weakness seen in the present case is the most common
symptom. The mean symptom duration in previous cases
was 15 months and ranged from 0.3 to 96 months. At the
present time, MRI is the best method for diagnosing spinal
cord tumors. However, distinction of tumor type based on
MRI findings remains difficult. The differential diagnosis
includes melanocytoma, intermediategrade melanocytic tumor,
and melanotic schwannoma3,4). Melanomas characteristically
show hyperintesity on T1-weighted images, hypointensity
on T2-weighted images, and homogeneous enhancement on
T1-contrast-enhanced images4). The paramagnetic properties
of melanin or intratumoral hemorrhage probably lead to
these findings4). However, these are also observable in other
melanocytic tumors. Thus, the ultimate diagnosis can only
be made on the basis of histopathological examination.
Melanocytoma is immunoreactive for HMB-45 and S-100
protein. In addition, the most specific feature of melanocy-
toma is the formation of tight nests surrounded by well
differentiated melonocytes with cytoplasm rich in melanin3).
Such disposition is absent in melanomas and in intermediate
grade-lesions. Intermediate-grade melanocytic tumors are
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Fig. 1. Sagittal magnetic resonance images (MRI) of thoracic area. A : T1-weighted MRI shows the spinal
cord tumor at the level of T4, which has high signal intensity relative to that of the cord and combined
syrinx. B : T2-weighted MRI shows homogenous signal hypointensity relative to that of the cord. C :
Contrast-enhanced T1-weighted MRI image shows homogenous enhancement.
A B C
Fig. 2. Microscopic finding. A : Photomicrograph shows atypical, bizarre cells with large pleomorphic
nuclei, macronucleoli, and mitoses (H & E,×1250). B : Immunohistochemical stains for human
melanoma black-45 (HMB-45) reveals cytoplasmic reactivity (H & E, ×1250).
A B
Fig. 3. Magnetic resonance images (MRI) obtained 3 years after surgery
showed no residual enhancing lesion in Gadolilium-enhanced T1-weighted
sagittal (A) and T2-weighed sagittal (B) view. Syrinx cavity was disappeared.
A B
differentiated from melanomas in the degree of hypercel-
lularity, cytologic atypia, and mitotic activity3). Melanotic
schwannomas show strong pericellular immunoreactivity for
collagen type IV, whereas melanocytomas typically show
perilobular and perivascular staining3). If the diagnosis of
spinal cord melanoma is made, differentiation of primary
melanoma from a metastatic lesion should be undertaken.
Whereas life expectancy is less than one year in patients with
metastatic melanoma to the CNS, a number of patients with
primary CNS melanoma experience long-term survival and
even cure3,11,17,19,20). This is the main reason why distinction
between primary and metastatic melanoma is important.
Primary spinal cord melanoma is diagnosed when the follow-
ing criteria, proposed by Hayward, are met : 1) there is no
malignant melanoma outside the central nervous system, and
2) the lesion is confirmed pathologically6). The present case
satisfied these criteria.
Treatment
Surgical resection has traditionally been the standard
treatment for primary spinal cord melanoma3,4,10). In the
literature, operation was performed in 26 patients. Complete
resection was achieved in 12 cases (46.2%), and subtotal
resection was achieved in 14 cases (53.8%). The efficacy of
radiotherapy and chemotherapy is still controversial5,7,14).
Radiotherapy was performed in 11 of 26 patients. The mean
radiation dose was 47 Gy and ranged from 30 to 60 Gy.
While radiation therapy has been performed by many au-
thors, the radiosensitivity of malignant melanoma is question-
able5). Stereotactic radiosurgery may be an alternative treat-
ment for this lesion2,18), but it needs further studies to define
its role. Two patients underwent intravenous chemotherapy.
One patient was treated with dacarbazine (DTIC)22), and the
other was treated with vincrisine, bleomycin, and cisplatin1).
They both lived at least one year. However, data on the res-
ponse to chemotherapy were not available in these two case
reports. Biotherapy-including interferon-α, interferon-γ,
interleukin-2, and lymphokine-activated killer (LAK) cells--
has been attempted in other melanomas and can be tried in
primary CNS melanoma21). At the present time there is no
data concerning the effect of radiotherapy or chemotherapy
on survival. Fifteen patients received no adjuvant therapy.
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Table 1. Summary of primary intramedullary spinal cord melanoma. Unobtainable data are left as blank
No Study Pub year Sex/Age Site Dr (m) Exo Op Adj Sv Last state
1 Bell7) 1930 C7-T1 Yes TR No
2 Da Costa16) 1939 T6 TR No
3 Woods16) 1944 F/62 T9 18 TR No 8 Dead
4 Roca16) 1954 L-S TR No
5 Gros16) 1956 T12-L1 TR No
6 Hirano and Carton7) 1959 M/42 T8-10 4 Yes TR RT (60Gy) 6.5 Dead
7 Kiel et al.9) 1961 F/33 C4-6 6 Yes STR No 25 Dead
8 Jung et al.8) 1974 F/62 C2-5 3 Yes TR No
9 Larson et al.11) 1987 M/73 T6-8 6 Yes STR RT (50Gy) 84 Alive
10 Larson et al.11) 1987 M/63 T2-9 96 No STR RT (60Gy) 156 Dead
11 Larson et al.11) 1987 F/67 T9-11 18 No STR RT (45Gy)
12 Larson et al.11) 1987 F/57 C1-3 3 Yes STR RT (50Gy) 30 Dead
13 Larson et al.11) 1987 F/69 T9-10 24 No STR No 44 Dead
14 Yoo et al.23) 1987 F/20 C7-T1 0.25 Yes STR No 17 Alive
15 Yamasaki et al.22) 1989 M/31 T6 6 Yes STR RT (50Gy) CT (DTIC) 12 Alive
16 Bae et al.1) 1996 M/41 C3-5 Yes STR RT (50Gy) CT (VBC) 14 Alive
17 Magni et al.12) 1996 M/64 T8 Yes TR No 18 Alive
18 Francois et al.5) 1998 M/62 T7-9 18 No TR No 28 Alive
19 Salame et al.17) 1998 F/76 T12-L2 6 No STR RT (30Gy) 15 Alive
20 Brat et al.3) 1999 F/71 T10 TR No 14 Alive
21 Brat et al.3) 1999 M/52 C1 STR RT (40Gy) 16 Alive
22 Brat et al.3) 1999 F/20 C4 STR No 20 Alive
23 Brat et al.3) 1999 F/57 C4 STR RT (54Gy) 8 Dead
24 Bidzinski 2000 M/36 C6-7 8 Yes TR RT (30Gy) 48 Alive
25 Farrokh et al.4) 2001 F/80 T12-L1 Yes STR No 9 Alive
26 Kounin et al.10) 2005 F/41 C2-4 9 Yes TR No 3 Alive
Adj : adjuvant therapy, CT : chemotherapy, DTIC : dacarbazine [5 (or 4)-(dimethyltriazeno) imidazole-4 (or 5)-carboxamide], Dr : duration, E : cauda equine, Exo : exophytosis,
IFN : interferon, Op : operation, Pub : published, RT : radiation therapy, STR : subtotal removal, Sv : survival duration, TR : total removal, VBC : vincristine, bleomycin and cisplatin
Among them, seven patients survived more than one year,
and three patients survived more than two years. However,
long-term follow-up data were not available for them.
Prognosis
Although the survival rate for CNS melanoma has not yet
been determined, the overall prognosis seems to be better
than that of cutaneous melanoma, which is usually fatal
within six months because of systemic involvement3,11,17,19,20).
The clinical course of CNS melanoma is unpredictable.
Larson et al.11) reported an average life expectancy of approxi-
mately seven years after surgery with radiotherapy. The mean
survival duration was 28.8 months and ranged from 3 to 156
months. Seventeen patients died during follow-up, and the
mean duration to death was 40 months and ranged from 8
to 156 months (Table 1). The characteristics of the CNS
might contribute to the indolent nature of this disease. In
contrast to cutaneous melanoma, lymphatic spread would be
difficult because there are no lymphatics in the spinal cord.
The blood-brain barrier of the spinal cord might also prevent
hematogenous spread. The variable clinical course of primary
spinal cord melanoma resembles primary uveal melanoma3).
While the natural history and prognostic parameters for
primary uveal melanoma are well delineated21), those for
primary spinal cord melanoma are not. The rarity of primary
spinal cord melanoma might be one reason for this. The
known prognostic parameters for primary uveal melanoma
are tumor diameter, patient age and gender, histological
features, and tumor location21). Older patients of male sex
have worse prognosis, as do patients with larger tumors of
the choroid and ciliary body. In 1931, Callender first classifi-
ed uveal melanomas into the following groups according to
the shape and differentiation status of the cells : spindle A cells
(fine chromatin and no distinct nucleoli), spindle B cells
(plumper nuclei, more nucleoli and coarser chromatin), and
epithelioid cells (pleomorphic)3). McLean reported that the
best prognosis was seen in pure spindle cell tumors, regardless
of type. A worse prognosis was seen in mixed tumors, and
the worst prognosis was seen in epithelioid cell tumors13).
Brat reported that CNS melanocytic neoplasms probably
share these features3). According to this classification system,
our case was in the spindle A cell classification, which has the
best prognosis. Retrospective review of histopathological
features was impossible, because histopathological photo-
micrographs were not available in many reports.
Follow-up
Because primary spinal cord melanoma has an unpre-
dictable clinical course, annual follow-up visits and MRI
follow-up are recommended for an extended period22).
CONCLUSION
Primary spinal cord melanoma is distinct from cutaneous
melanoma, and its clinical course is unpredictable. Long-
term study in a large series is necessary to delineate the natu-
ral history, prognostic parameters, and treatment modalities
for primary spinal cord melanoma. The present case shows
that complete resection alone, without any adjuvant therapy,
may result in a favorable outcome for primary spinal cord
melanoma of pure spindle cell type.
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